GB9403250D0 - Therapeutic use of myelin-associated glycoprotein (mag) - Google Patents

Therapeutic use of myelin-associated glycoprotein (mag)

Info

Publication number
GB9403250D0
GB9403250D0 GB9403250A GB9403250A GB9403250D0 GB 9403250 D0 GB9403250 D0 GB 9403250D0 GB 9403250 A GB9403250 A GB 9403250A GB 9403250 A GB9403250 A GB 9403250A GB 9403250 D0 GB9403250 D0 GB 9403250D0
Authority
GB
United Kingdom
Prior art keywords
myelin
mag
therapeutic use
associated glycoprotein
glycoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB9403250A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Original Assignee
McGill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McGill University filed Critical McGill University
Priority to GB9403250A priority Critical patent/GB9403250D0/en
Publication of GB9403250D0 publication Critical patent/GB9403250D0/en
Application status is Pending legal-status Critical

Links

GB9403250A 1994-02-21 1994-02-21 Therapeutic use of myelin-associated glycoprotein (mag) Pending GB9403250D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9403250A GB9403250D0 (en) 1994-02-21 1994-02-21 Therapeutic use of myelin-associated glycoprotein (mag)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9403250A GB9403250D0 (en) 1994-02-21 1994-02-21 Therapeutic use of myelin-associated glycoprotein (mag)
AU17035/95A AU1703595A (en) 1994-02-21 1995-02-17 Therapeutic use of myelin-associated glycoprotein (mag)
PCT/CA1995/000089 WO1995022344A1 (en) 1994-02-21 1995-02-17 Therapeutic use of myelin-associated glycoprotein (mag)
CA 2183630 CA2183630A1 (en) 1994-02-21 1995-02-17 Therapeutic use of myelin-associated glycoprotein (mag)
SE9703032A SE9703032D0 (en) 1994-02-21 1997-08-21 Therapeutic use of myelin associated glykoportein

Publications (1)

Publication Number Publication Date
GB9403250D0 true GB9403250D0 (en) 1994-04-13

Family

ID=10750657

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9403250A Pending GB9403250D0 (en) 1994-02-21 1994-02-21 Therapeutic use of myelin-associated glycoprotein (mag)

Country Status (5)

Country Link
AU (1) AU1703595A (en)
CA (1) CA2183630A1 (en)
GB (1) GB9403250D0 (en)
SE (1) SE9703032D0 (en)
WO (1) WO1995022344A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2225691A1 (en) * 1995-06-27 1997-01-16 Research Foundation Of Cuny, Hunter College Compositions and methods using myelin-associated glycoprotein (mag) and inhibitors thereof
CA2190418A1 (en) * 1996-11-15 1998-05-15 Zhi-Cheng Xiao Neuron and neural tumor growth regulatory system, antibodies thereto and uses thereof
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
WO1999060021A2 (en) * 1998-05-19 1999-11-25 Yeda Research And Development Co. Ltd. Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
AU3134799A (en) * 1998-04-16 1999-11-08 Peter Erich Braun Nevron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
WO2002014537A2 (en) * 2000-08-14 2002-02-21 Fallon Joan M Methods for diagnosing and treating dysautonomia and other dysautonomic conditions
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
ES2668909T3 (en) 2009-01-06 2018-05-23 Galenagen, Llc Compositions comprising protease, amylase and lipase for use in the treatment of Staphylococcus aureus infections
EP2373693A4 (en) 2009-01-06 2012-04-25 Curelon Llc Compositions and methods for the treatment or the prevention oral infections by e. coli
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
GB2503852B (en) 2011-04-21 2018-12-12 Curemark Llc Compounds for the treatment of neuropsychiatric disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1721092A1 (en) * 1990-02-26 1992-03-23 Институт Цитологии Ан Ссср Strain of hydride cultured mammalian cells mus musculus l - a producer of monoclonal antibody to brain myelin glycoproteine, inhibiting activity of natural human killers

Also Published As

Publication number Publication date
AU1703595A (en) 1995-09-04
SE9703032D0 (en) 1997-08-21
WO1995022344A1 (en) 1995-08-24
CA2183630A1 (en) 1995-08-24

Similar Documents

Publication Publication Date Title
IL101818D0 (en) Therapeutic agent
GB9518115D0 (en) Triazole derivatives and their use as therapeutic agents
GB9311920D0 (en) Therapeutic agents
HK1003570A1 (en) Therapeutic amides
GB9322976D0 (en) Therapeutic agents
GB9213181D0 (en) Therapeutic agents
GB9114760D0 (en) Therapeutic agents
GB9126260D0 (en) Therapeutic agents
GB9121028D0 (en) Therapeutic agents
HRP960270A2 (en) Therapeutic amides
GB9315808D0 (en) Therapeutic agents
GB9306578D0 (en) Therapeutic agents
GB9525296D0 (en) Therapeutic agents
ZA9309583B (en) Therapeutic combination
IL104170D0 (en) Therapeutic agents
HRP960349A2 (en) Therapeutic agents
GB9218322D0 (en) Therapeutic agents
GB9210393D0 (en) Therapeutic agents
GB9505491D0 (en) Therapeutic agents
GB9513118D0 (en) Therapeutic agents
OA10363A (en) Therapeutic amides
GB9222486D0 (en) Therapeutic agents
GB9119704D0 (en) Therapeutic agents
GB9220286D0 (en) Therapeutic agents
GB9300051D0 (en) Therapeutic agents